Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

271
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
271
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

46
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
46
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

91
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
91
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

96
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
96
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

85
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
85
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

647
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
647

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial.

Rheumatology (Oxford, England)·2026
Same author

Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition.

Journal of autoimmunity·2026
Same author

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same author

20 years of progress in the classification of immune-mediated diseases.

Nature reviews. Rheumatology·2026
Same author

Two Patterns of Sacroiliac Joint Bone Marrow Oedema are apparent in AxSpA Determined by HLA-B27 Status, Body Mass Index or Psoriasis.

Joint bone spine·2026
Same author

Better communication between rheumatologists and radiologists is key to improving MRI requesting and reporting data in axial spondyloarthritis: audit data from a single specialist centre.

Rheumatology advances in practice·2026

Related Experiment Video

Updated: Nov 8, 2025

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

843

Vasculitis therapy refines vasculitis mechanistic classification.

Christopher Kirkegaard Torp1, Mads Brüner1, Kresten Krarup Keller2

  • 1Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Autoimmunity Reviews
|April 19, 2021
PubMed
Summary
This summary is machine-generated.

This review of vasculitis treatments suggests a new classification based on immune mechanisms. Targeted therapies like interleukin inhibitors and anti-CD20 treatments reveal distinct pathways for different vasculitis types.

Keywords:
AbataceptAdlimumabAntineutrophil cytoplasmic antibody-associated vasculitisAvacopanChurg-StraussEosinophilic granulomatosis with polyangiitisEtanerceptGiant cell arteritisGranulomatosis with polyangiitisInfliximabLarge vessel vasculitisMepolizumabMicroscopic polyangiitisRituximabSecukinumabSmall vessel vasculitisTakayasu arteritisTemporal arteritisTocilizumabUstekinumabWegeners granulomatosis

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.6K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.5K

Related Experiment Videos

Last Updated: Nov 8, 2025

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

843
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.6K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.5K

Area of Science:

  • Immunology
  • Rheumatology
  • Clinical Trials

Background:

  • Primary vasculitides are immune-mediated diseases with complex pathogenesis.
  • Current classification relies on affected blood vessel size (Chapel Hill classification).
  • Biologic therapies offer insights into underlying pathogenic mechanisms.

Purpose of the Study:

  • To systematically review evidence for a refined, mechanistic immunological classification of vasculitis.
  • To analyze clinical trial data on targeted immunotherapies.

Main Methods:

  • Systematic literature review of 40 studies (20 RCTs, 16 prospective, 1 retrospective, 3 case series).
  • Qualitative assessment of clinical studies involving biologic therapies.

Main Results:

  • Interleukin 6 receptor inhibition (tocilizumab) effective for large vessel vasculitis.
  • Anti-CD20 (rituximab) and C5a receptor antagonist (avacopan) show promise for granulomatosis with polyangiitis and microscopic polyangiitis.
  • Interleukin 5 inhibition (mepolizumab) is key for eosinophilic granulomatosis with polyangiitis.
  • TNF-alpha inhibitors had mixed results in giant cell arteritis and Takayasu arteritis.

Conclusions:

  • Clinical studies with targeted drugs support a mechanistic immunological classification of vasculitis.
  • Cytokine antagonism highlights immunological differences between vasculitis subtypes.
  • This approach refines understanding beyond vessel size classification.